NEWS
Zepbound Becomes the First FDA-Approved Drug for Obstructive Sleep Apnea
Tirzepatide (Zepbound) is now FDA-approved for OSA. Trial outcomes, who qualifies, and how to use alongside CPAP and lifestyle.
Dr. Sarah Chen
November 3, 2025
6 min read
Zepbound Becomes the First FDA-Approved Drug for Obstructive Sleep Apnea
Tirzepatide (Zepbound) received FDA approval as the first pharmacotherapy for obstructive sleep apnea (OSA), reflecting robust reductions in apnea–hypopnea events and meaningful weight loss in trials.
Key Trial Findings
- Significant AHI reductions vs placebo.
- Resolution or downgrading of moderate-to-severe OSA in a substantial subset.
- Weight loss and cardiometabolic improvements as complementary benefits.
Practical Use
- Continue CPAP where indicated; Zepbound can be additive.
- Emphasize resistance training to preserve lean mass.
- Monitor AHI, daytime sleepiness, BP, weight, and GI tolerability.
- Significant AHI reductions vs placebo.
- Resolution or downgrading of moderate-to-severe OSA in a substantial subset.
- Weight loss and cardiometabolic improvements as complementary benefits.
Practical Use
- Continue CPAP where indicated; Zepbound can be additive.
- Emphasize resistance training to preserve lean mass.
- Monitor AHI, daytime sleepiness, BP, weight, and GI tolerability.
About Dr. Sarah Chen
Endocrinologist and peptide research specialist with 15+ years of experience in metabolic medicine.
EndocrinologySleep MedicineMetabolic Health
Related Articles
NEWS
Navigating the GLP-1 Gray Market: Access, Affordability, and Safety in 2025
High demand and limited coverage have pushed some to gray-market GLP-1s. Learn the risks, legal context, safer access routes, and cost strategies.
Dr. Sarah Chen
Nov 3, 2025
8 min read
GLP-1 medicationsgray marketOzempic+3 more
CLINICAL TRIALS
How GLP-1 Medications Are Reshaping Consumer Behavior and Markets
From grocery baskets to wellness spend, GLP-1s are changing consumer habits. What brands and patients should know.
Dr. James Wilson
Nov 3, 2025
7 min read
GLP-1 medicationsconsumer behaviormarket trends+2 more
WEIGHT LOSS
GLP-1 Receptor Agonists and Alcohol: What Early Studies Show in Obesity
Preliminary data suggest GLP-1 RAs may alter alcohol’s physiological and perceptual effects in people with obesity. What to know and discuss with your clinician.
Dr. Sarah Chen
Nov 3, 2025
6 min read
GLP-1 receptor agonistsalcohol consumptionobesity+1 more